SYBX Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 22:00):

Stats
Dagens volum	29 899.00
Gjennomsnittsvolum	136 888
Markedsverdi	21.39M
EPS	$0 ( 2024-04-03 )
Neste inntjeningsdato	( $-0.800 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.210
ATR14	$0.0270 (1.44%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-02	Dooley Mary Beth	Sell	188	Common Stock
2024-04-02	Awad Antoine	Sell	372	Common Stock
2024-03-18	Dooley Mary Beth	Sell	0	Common Stock
2024-03-18	Dooley Mary Beth	Sell	3 612	Stock Option (right to buy)
2024-03-19	Flynn James P	Buy	4 000	Stock Option (right to buy)

INSIDER POWER
-63.47
Last 97 transactions
Buy: 6 126 214 \| Sell: 2 856 834

Synlogic Inc Korrelasjon

10 Mest positive korrelasjoner
SJ	0.953
PRSO	0.947
SGML	0.945
DCOM	0.941
EXTR	0.94
MATW	0.939
HAFC	0.938
SHBI	0.936
KRNY	0.932
CHTR	0.931

10 Mest negative korrelasjoner
ATCX	-0.937
IIN	-0.927
MOR	-0.924
META	-0.921
TESS	-0.919
TA	-0.918
ECHO	-0.91
SGIIU	-0.909
TACO	-0.909
LIBY	-0.906

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Synlogic Inc Økonomi

Annual	2023
Omsetning:	$3.37M
Bruttogevinst:	$-1.92M (-57.08 %)
EPS:	$-8.81

FY	2023
Omsetning:	$3.37M
Bruttogevinst:	$-1.92M (-57.08 %)
EPS:	$-8.81

FY	2022
Omsetning:	$1.18M
Bruttogevinst:	$-4.49M (-380.42 %)
EPS:	$-13.57

FY	2021
Omsetning:	$1.75M
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-1.090

Financial Reports:

No articles found.

Synlogic Inc

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate to treat homocystinuria; and SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase I clinical trial for the treatment of enteric hyperoxaluria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd; Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.

Sanntidsoppdatering for Synlogic Inc [SYBX]

Upcoming Earnings Alert